Leinco is founded.
Tasuku Honjo and his team at Kyoto University discover the PD-1 immune checkpoint receptor and its role in programmed cell death.
FDA approves rituximab, for use in patients with B-Cell Non-Hodgkin Lymphoma. the first monoclonal antibody approved for use in cancer therapy
Following successful Phase 3 trials of 925 untreated metastatic colon cancer patients, the first VEGF-inhibitor is approved by the FDA.
Leinco Technologies licensed clone 9H10, Anti-mouse CTLA-4 from James Allison a future Nobel Prize winner.
Leinco upgraded to 4th state-of-the-art antibody and protein manufacturing facility with Missouri Governor Nixon in attendance.
Leinco Technologies became ISO9001 Certified as a requirement to manufacture raw materials for use in in vitro diagnostic devices.
Leinco Technologies licensed and added key checkpoint blockade antibodies like Clone RMP1-14. 9d9, C9B7W, and others.
Nobel Prize in Medicine to the two immunologists who were at the origin of the concept of ICI-based immunotherapy, James Allison and Tasuku Honjo.
Leinco released the first antibodies against SARS-CoV2 RBD which played an early and key role in mAb therapies. research and diagnostics of COVID19 disease.
Continuing the fight against infectious diseases, Leinco made antibodies and proteins against other key viral targets (Zika, RSV, Dengue, Chikungunya, Rotavirus and more).